



10745 Westside Way, Suite 200

Alpharetta, GA 30009

Tel: +1 (844) 884 5367

Email: [info@vtivision.com](mailto:info@vtivision.com)

[www.vtivision.com](http://www.vtivision.com)

[www.vtivisioninvestors.com](http://www.vtivisioninvestors.com) (for investors)

## ASX Announcement

### ***Visioneering Launches NaturalVue® Brand Contact Lenses for Myopia Progression Control & Presbyopia in the United Kingdom***

*Innovative multifocal contact lens establishes presence in Europe's largest market*

#### **Investment highlights**

- Visioneering Technologies, Inc. has launched innovative NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses in the UK, Europe's largest market for contact lenses
- The unique, patented lens features Neurofocus Optics® technology which makes NaturalVue Multifocal an ideal solution for presbyopia and myopia progression control
- The company will be exhibiting at Optometry Tomorrow 2019 in Birmingham 24-25 February

**Atlanta, Georgia, 20 February 2019:** US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses **Visioneering Technologies, Inc (ASX: VTI)** ('Visioneering' or 'The Company') has announced its launch into the UK.

The NaturalVue Multifocal contact lens (NVMF) employs VTI's Neurofocus Optics® technology to address two of the largest global eye conditions, progressive nearsightedness in children (paediatric myopia progression), and the loss of ability by adults over 40 to see close objects (presbyopia). NVMF's optical characteristics allow the very same lenses to be used in the treatment of both of these conditions.

Pediatric Myopia has undergone explosive growth on a global scale over the past four decades and has become a major worldwide eye health issue<sup>1,2</sup>. Eye experts generally believe that minimizing the progression of nearsightedness is an important intervention aimed at minimizing lifetime risks of blindness and other serious ocular diseases that are related to nearsightedness<sup>3</sup>.

Eye care practitioners (ECP's) have been eager to try the NaturalVue Multifocal on their patients experiencing myopia progression. In October 2018, Chester, UK optician, Andrew D Price FBDO(Hons)CL COA, became the first ECP to fit VTI contact lenses in the United Kingdom. He commented, "The lenses have been shown to slow myopia progression in children<sup>4</sup>, and to provide excellent near and distance vision in presbyopic adults<sup>5</sup>. I'm very pleased to add Visioneering's NaturalVue Multifocal 1 Day Contact Lenses to my options for nearsighted children."

As part of its international expansion, VTI will exhibit at the Optometry Tomorrow ("OT") 2019 event, 24-25 February 2019, at the Hilton Birmingham Metropole, The NEC Birmingham, Birmingham, UK. The OT will offer lectures and presentations from the world's leading experts in myopia and will provide focused education and resources to eye care professionals to increase awareness of the importance of controlling myopia progression in children.

**Visioneering CEO Dr. Stephen Snowdy, said:** "Following successful launches in Australia, New Zealand and Nordic markets in late 2018, we are pleased to make this revolutionary product available to patients and practitioners in the United Kingdom. And, our international expansion will

not stop there; we are also preparing additional geographies for launch in 2019, including Canada, and some Asian markets.”

## Ends

For more information, please contact:

<i>Company</i>	<i>Investor and media relations</i>
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: <a href="mailto:ssnowdy@vtivision.com">ssnowdy@vtivision.com</a>	Julia Maguire The Capital Network M: +61 419 815 386 E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a>

**NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens Indication for Use in Europe and Australia and New Zealand:** NaturalVue (etafilcon A) Multifocal Daily Disposable Soft (Hydrophilic) Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia) and/or presbyopia, and myopia progression control in aphakic and/or non-aphakic persons with non-diseased eyes in powers from -20.00 to +20.00 dioptres and with non-diseased eyes who may require a reading addition of up to +3.00D. The lenses may be worn by persons who exhibit astigmatism of 2.00 dioptres or less that does not interfere with visual acuity.

### About VTI:

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

### Foreign Ownership Restriction:

VTI's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of VTI's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements:

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product as well as, our expectations with respect to our ability to develop and commercialize new products.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

MKT-VTI-ASX6 r0

- 1 Vitale, S., Sperduto, R., & Ferris, F. (2009). Increased Prevalence of Myopia in the United States Between 1971-1972 and 1999-2004. *Archives of Ophthalmology*. 127(12): 1632-1639
- 2 Dolgin, E. (2015). The myopia boom. *Nature*. 519(7543): 276-278.
- 3 Flitcroft, D. (2012). The complex interactions of retinal, optical and environmental factors in myopia aetiology. *Progress in Retinal and Eye Research*. 31(6): 622-660.
- 4 Cooper J, O'Connor, B, Watanabe R, Fuerst R, Berger S, Eisenberg N, Dillehay SM. Case series analysis of myopic progression control with a unique extended depth of focus multifocal contact lens. *Eye & Contact Lens*. 2018 Sep;44(5):e16-e24.
- 5 VTI Data on file, 2015. N=59. Data assessed after 1 week of wear.